drugset / Trial / NCT05469646

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated

NCT05469646

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1819479 in healthy male Japanese subjects receiving single rising doses (SRD) in order to provide the basis for a clinical development of BI 1819479 in Japan.

Timeline

Start
2022-08-03
Primary completion
2022-12-20
Completion
2022-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1819479 Unknown

Indications

No indication recorded.